This is a working overview of cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-03. Anything still debated is marked as such rather than presented as settled.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
28 July DeepMind announces that its AlphaFold program has uncovered the structures of more than 200 million folded proteins, essentially all of those known to science. Researchers report the development of a wearable bioadhesive stretchable high-resolution ultrasound imaging patch for days-long continuous imaging of diverse organs which may enable novel diagnostic and monitoring tools. First reported discovery of an animal helping algae reproduce after pollination in the sea was first reported in 2016. Researchers report the development of nanoscale brain-inspired artificial synapses, using the ion proton (H+), for 'analog deep learning'. Scientists report the discovery of chemical reactions by potential primordial soup components that produced amino acids and may be part of the origin of life on Earth. 29 July In a preprint, scientists from the Galileo Project describe a planned expedition to retrieve small fragments of interstellar meteor CNEOS 2014-01-08, which "appears to be rare both in composition and in speed" and is not ruled out to be "extraterrestrial equipment", using a magnetic sled on the seafloor of the impact region. A study, that reanalyzes data used in a study by DeSilva et al. (2021), indicates that human brain size did not decrease over the last three thousand years as suggested by this study nor within 300 ka as suggested by other studies. It concludes that "the samples need to be specific enough to test the hypothesis across different times and populations".
=== Moving-belt interface === The moving-belt interface (MBI) was developed by McFadden et al. in 1977 and commercialized by Finnigan. This interface consisted of an endless moving belt onto which the LC column effluent was deposited in a band. On the belt, the solvent was evaporated by gently heating and efficiently exhausting the solvent vapours under reduced pressure in two vacuum chambers. After the liquid phase was removed, the belt passed over a heater which flash desorbed the analytes into the MS ion source. One of the significant advantages of the MBI was its compatibility with a wide range of chromatographic conditions. MBI was successfully used for LC–MS applications between 1978 and 1990 because it allowed coupling of LC to MS devices using EI, CI, and fast-atom bombardment (FAB) ion sources. The most common MS systems connected by MBI interfaces to LC columns were magnetic sector and quadrupole instruments. MBI interfaces for LC–MS allowed MS to be widely applied in the analysis of drugs, pesticides, steroids, alkaloids, and polycyclic aromatic hydrocarbons. This interface is no longer used because of its mechanical complexity and the difficulties associated with belt renewal (or cleaning) as well as its inability to handle very labile biomolecules.
Hydrolysis of the alpha-linked peptide bond in the sequence Gly-Gly-!Ala-Thr-Tyr at the C-terminal end of the small ubiquitin-like modifier (SUMO) propeptide, Smt3 The enzyme from Saccharomyces cerevisiae can also recognize small ubiquitin-like modifier 1 (SUMO-1) from human.
== History of paper chromatography == The discovery of paper chromatography in 1943 by Martin and Synge provided, for the first time, the means of surveying constituents of plants and for their separation and identification. Erwin Chargaff credits in Weintraub's history of the man the 1944 article by Consden, Gordon and Martin. There was an explosion of activity in this field after 1945.
Studies of twin adults indicate a 0.36 to 0.48 genetic influence on the likelihood of developing migraine. However, few studies examine non-European populations or distinguish between migraine with aura and migraine without aura. It is clear from family and population studies that migraine is a complex disorder, where numerous genetic risk variants exist, and where each variant increases the risk of migraine marginally. It is also known that having several of these risk variants increases the risk by a small to moderate amount. Single gene disorders that result in migraine are rare. One of these is known as familial hemiplegic migraine, a type of migraine with aura, which is inherited in an autosomal dominant fashion. Three main genes are involved in familial hemiplegic migraine via ion transport: CACNA1A, ATP1A2, and SCN1A. Another genetic disorder that has been associated with migraine is CADASIL syndrome (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). Despite some similarities in symptoms, ICHD-3 recommends using the diagnosis "headache attributed to CADASIL" (code 6.8.1) rather than migraine with aura (MA) or migraine without aura (MO) (codes 1.1 and 1.2). The TRPM8 gene, which codes for a cation channel, has been linked to migraine. One meta-analysis found a protective effect from angiotensin converting enzyme polymorphisms on migraine. The common forms of migraine are polygenetic, where common variants of numerous genes contribute to the predisposition for migraine.
Sources: en.wikipedia.org
Emus form breeding pairs during the summer months of December and January and may remain together for about five months. During this time, they stay in an area a few kilometres in diameter and it is believed they find and defend territory within this area. Both males and females put on weight during the breeding season, with the female becoming slightly heavier at between 45 and 58 kg (99 and 128 lb). Mating usually takes place between April and June; the exact timing is determined by the climate as the birds nest during the coolest part of the year. During the breeding season, males experience hormonal changes, including an increase in luteinising hormone and testosterone levels, and their testicles double in size. Males construct a rough nest in a semi-sheltered hollow on the ground, using bark, grass, sticks and leaves to line it. The nest is almost always a flat surface rather than a segment of a sphere, although in cold conditions the nest is taller, up to 7 cm (2.8 in) tall, and more spherical to provide some extra heat retention. When other material is lacking, the bird sometimes uses a spinifex tussock a metre or so across, despite the prickly nature of the foliage. The nest can be placed on open ground or near a shrub or rock. The nest is usually placed in an area where the emu has a clear view of its surroundings and can detect approaching predators. The nest can contain eggs from multiple emus: the number is usually between 15 and 25 eggs.
Mumps vaccines are vaccines which prevent mumps. When given to a majority of the population they decrease complications at the population level. Effectiveness when 90% of a population is vaccinated is estimated at 85%. Two doses are required for long term prevention. The initial dose is recommended between 12 and 18 months of age. The second dose is then typically given between two years and six years of age. Usage after exposure in those not already immune may be useful. Side effects are usually mild. It may cause "slight soreness and swelling" at the site of injection, parotisis and mild fever. More significant side effects are rare. Evidence is insufficient to link the vaccine to complications such as neurological effects (beyond "occasional orchitis and sensorineural deafness"). The vaccine should not be given to people who are pregnant or have very poor immune system function. Poor outcomes among children of mothers who received the vaccine during pregnancy, however, have not been documented. Even though the vaccine is developed in chicken cells, it is generally safe to give to those with egg allergies. Most of the developed world and many countries in the developing world include it in their immunization programs often in combination with measles and rubella vaccine known as MMR. A formulation with the previous three and the varicella (chickenpox) vaccine known as MMRV is also available. As of 2005, 110 countries provided the vaccine as part of their immunization programs.
==== Entrepreneurial ==== The entrepreneurial model looks at either the individual criminal or a smaller group of organized criminals, that capitalize off the more fluid 'group-association' of contemporary organized crime. This model conforms to social learning theory or differential association in that there are clear associations and interaction between criminals where knowledge may be shared, or values enforced, however, it is argued that rational choice is not represented in this. The choice to commit a certain act, or associate with other organized crime groups, may be seen as much more of an entrepreneurial decision – contributing to the continuation of a criminal enterprise, by maximizing those aspects that protect or support their own individual gain. In this context, the role of risk is also easily understandable, however it is debatable whether the underlying motivation should be seen as true entrepreneurship, or entrepreneurship as a product of some social disadvantage. The criminal organization, much in the same way as one would assess pleasure and pain, weighs such factors as legal, social and economic risk to determine potential profit and loss from certain criminal activities. This decision-making process rises from the entrepreneurial efforts of the group's members, their motivations and the environments in which they work.
=== Lung transplantation === Lung transplantation may be suitable for those patients physically eligible to undergo a major transplant operation. In IPF patients, lung transplant has been shown to reduce the risk of death by 75% as compared with patients who remain on the waiting list. Since the introduction of the lung allocation score (LAS), which prioritizes transplant candidates based on survival probability, IPF has become the most common indication for lung transplantation in the USA. Symptomatic patients with IPF younger than 65 years of age and with a body mass index (BMI) ≤26 kg/m2 should be referred for lung transplantation, but there are no clear data to guide the precise timing for LTx. Although controversial, the most recent data suggest that bilateral lung transplantation is superior to single lung transplantation in patients with IPF. Five-year survival rates after lung transplantation in IPF are estimated at between 50 and 56%.
Sources: en.wikipedia.org
However, conflict continued in the southern and central parts of the country. Within months, the TFG had gone from holding about 70% of south-central Somalia's conflict zones, to losing control of over 80% of the disputed territory to the Islamist insurgents.
Black pearl pepper: small cherry-shaped fruits and dark brown to black leaves Black Hungarian pepper: green foliage, highlighted by purple veins and purple flowers, jalapeño-shaped fruits Bishop's crown pepper, Christmas bell pepper: named for its distinct three-sided shape resembling a red bishop's crown or a red Christmas bell
=== Myocardium / cardiomyopathy === (I40) Acute myocarditis (I41) Myocarditis in diseases classified elsewhere (I42) Cardiomyopathy (I42.0) Dilated cardiomyopathy (I42.1) Obstructive hypertrophy cardiomyopathy (I42.2) Other hypertrophic cardiomyopathy (I42.3) Endomyocardial (eosinophilic) disease Eosinophilic myocarditis Endomyocardial (tropical) fibrosis Löffler's endocarditis (I42.4) Endocardial fibroelastosis (I42.5) Other restrictive cardiomyopathy (I42.6) Alcoholic cardiomyopathy (I42.8) Other cardiomyopathies Arrhythmogenic right ventricular dysplasia (I43) Cardiomyopathy in diseases classified elsewhere
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.